HMG 75IU Kit
$90.00
(CAS 9002-68-0); WHO International Standard for Menotropins (IS 80/552); European Pharmacopoeia Monograph 0128; clinical guidelines from American Society for Reproductive Medicine (ASRM); product monographs (Pergonal®, Menopur®).
Description
🧪 Product Profile: Human Menopausal Gonadotropin (HMG)
Product Name: Human Menopausal Gonadotropin (HMG)
CAS Number: 9002-68-0
Synonyms: Menotropins; Pergonal; Humegon; Gonadotropin, human menopausal
Molecular Composition: Glycoprotein heterodimer complex containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activities in ~1:1 ratio
Molecular Weight: FSH ~34 kDa; LH ~29 kDa
Source: Purified from urine of postmenopausal women
Purity: ≥95% protein (SDS-PAGE); biological activity ratio (FSH:LH) ~1:1 (IU/IU)
Formulation: Lyophilized powder for injection (standard vials: 75 IU FSH + 75 IU LH, 150 IU FSH + 150 IU LH)
🔬 Key Characteristics
Human Menopausal Gonadotropin (HMG) is a purified extract of gonadotropic hormones obtained from the urine of postmenopausal women, where ovarian follicle depletion leads to elevated endogenous gonadotropin secretion. It contains a balanced ratio of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activities, mimicking the physiological gonadotropin profile required for folliculogenesis. The glycoprotein structure features carbohydrate moieties (16-25% by weight) essential for receptor binding and metabolic stability. As a biogenic preparation, HMG exhibits batch-to-batch consistency in hormonal activity through bioassay standardization against the WHO International Standard for Menotropins.
⚙️ Mechanism of Action
- Folliculogenesis Stimulation: FSH component binds to granulosa cell receptors, activating adenylate cyclase and cAMP-dependent pathways to promote follicle maturation from primordial to antral stages. Induces aromatase activity, converting androgens to estrogens (estradiol) to support endometrial proliferation.
- Luteinizing Activity: LH acts on theca cells to stimulate androgen synthesis (androstenedione), providing substrate for follicular estrogen production. In later follicular phase, LH surge triggers oocyte meiosis resumption and ovulation when administered in high doses.
- Ovarian Steroidogenesis: Synergistic FSH/LH action upregulates cholesterol side-chain cleavage enzyme (CYP11A1), enhancing progesterone synthesis in luteinized granulosa cells.
- Male Gonadal Effects: Stimulates Leydig cell testosterone production and Sertoli cell spermatogenesis in hypogonadotropic hypogonadism, via LH and FSH receptor activation respectively.
📊 Clinical & Research Applications
- Reproductive Medicine: First-line therapy for anovulatory infertility (WHO Group II) and controlled ovarian hyperstimulation (COH) in assisted reproductive technologies (ART), including IVF and ICSI.
- Male Infertility: Treatment of hypogonadotropic hypogonadism (HH) to induce spermatogenesis in prepubertal males and improve sperm count in adult males with gonadotropin deficiency.
- Endocrinology Research: In vitro model systems for follicle culture, ovarian steroidogenesis studies, and gonadotropin receptor signaling pathway analysis.
- Pharmacology Development: Bioactivity reference standard for recombinant gonadotropin analogs (e.g., rFSH, corifollitropin alfa).
💡 Product Features
- Bioactivity: Standardized by biological assay in rats (ovarian weight gain method for FSH; ventral prostate weight method for LH). Specific activity ≥75 IU/mg protein.
- Administration: Intramuscular or subcutaneous injection; typically administered daily starting on menstrual cycle day 2-3, with dosage adjusted based on follicular response (ultrasound and estradiol monitoring).
- Stability: Lyophilized powder stable for 36 months at 2-8°C; reconstituted solution (with bacteriostatic water) stable for 24 hours at room temperature or 72 hours refrigerated.
- Combination Therapy: Co-administered with human chorionic gonadotropin (hCG) to trigger ovulation once follicular maturity is achieved (typically when leading follicle reaches 18-20mm).
⚠️ Safety Considerations
- Ovarian Hyperstimulation Syndrome (OHSS): Risk of severe OHSS (incidence ~1-5%) characterized by ovarian enlargement, ascites, and thromboembolic complications; requires careful dose titration and monitoring.
- Multiple Pregnancy: Increased incidence of multiple gestations (15-20%) compared to natural conception; higher order multiples (triplets+) reduced with modern ART protocols.
- Contraindications: Primary ovarian failure, uncontrolled thyroid/adrenal dysfunction, pituitary tumor, abnormal uterine bleeding of undetermined origin, and hypersensitivity to urinary-derived proteins.
- Immunogenicity: Potential for anti-FSH/LH antibody formation with prolonged use, though clinical significance is rare.



